Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces first occupant in ‘science incubator’

Pfizer announces first occupant in ‘science incubator’

20th July 2007

Pfizer has announced the first occupant of The Pfizer Incubator (TPI), a programme through which scientist-entrepreneurs can bring medical innovations to patients through the contribution of novel ideas to solve difficult technical and scientific challenges.

TPI also provides scientists with the required resources to develop these ideas into actual practice.

Assistant professor at the Scripps Research Institute Vaughn Smider will be the first occupant at TPI and work to develop new technology for the identification of antibodies that have the potential to result in new treatment options.

Professor Smider will build a new company, Fabrus, at the incubator and over a two-year period will develop antibody libraries and the means of screening these against biological targets in some of the 11 disease areas explored by Pfizer.

Alex Polinsky, head of the TPI, said: “We’ve had a really warm reception from the biotech community and academic scientists.

“We are helping to fill the need for support and funding for early scientific work. The Incubator is a channel that brings innovation one step closer to patients.”

He added that the work of Fabrus could lead to the development of technology providing a number of new treatment options in a range of therapeutic areas.

Earlier this week, Pfizer announced its financial results for the second-quarter of the 2007 fiscal year, recording revenues of $11.1 billion (5.4 billion pounds), a six per cent drop on the same period last year.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.